Shiv Saidha MBBCh, MD, MRCPI
Professor of Neurology, Division of Neuroimmunology and Neurological Infections, Johns Hopkins Hospital, Baltimore, MarylandDr. Shiv Saidha specializes in the diagnosis, management, and treatment of multiple sclerosis (MS), as well as other neuroimmunological disorders of the central nervous system, including those afflicting the brain, spinal cord, and optic nerves.
Dr. Saidha received his medical degree, as well as his postgraduate Doctor of Medicine, from the National University of Ireland, Galway (NUIG), Ireland. He completed residency training in general internal medicine and neurology in Ireland. He then completed a three year specialized fellowship training program in neuroimmunology & neuroinfectious diseases at Johns Hopkins University School of Medicine, Baltimore, Maryland. He is currently a Professor of Neurology at Johns Hopkins University School of Medicine.
Dr. Saidha’s research interests to date have predominantly focused on the non-invasive interrogation of retinal structures using optical coherence tomography (OCT) and OCT angiography (OCTA) in multiple sclerosis (MS), in order to identify and investigate novel outcome strategies for assessing and monitoring neuroprotection and neurorestoration in MS, as well as to further our understanding of the pathobiology of MS, including how retinal pathology in MS may be related to more global central nervous system disturbances. He has been at the fore of discovering and demonstrating that inner and outer retinal layer pathology occur within the unmyelinated retina in MS (both quantitatively and qualitatively). He is committed to continuing to delineate and ascertain the mechanisms involved in the development of these findings, the clinical relevance of these changes (both locally in the retina, as well as more globally), and determine if this information may be used to guide the development of new, and potentially unique/novel effective MS therapies. His work to date has been primarily structurally focused (both within the retina using OCT and OCTA, as well as more globally within the central nervous system through the assessment of brain substructure volumes, diffusion tensor imaging & magnetization transfer ratio metrics within specific pathways in MS). He also has expertise in the functional assessment of the anterior visual pathway in MS through the application of multifocal electroretinography, pupillometry, macular pigment optical density, and retinal function imaging techniques, amongst others, as well as of global and regional brain metabolism. He has published papers in Lancet, Lancet Neurology, Annals of Neurology, Brain, Neurology, JAMA Neurology, and Multiple Sclerosis Journal, amongst others.
Disclosures
Dr. Saidha has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Novartis, Genentech Corporation, TG therapeutics & Bristol Myers Squibb. He has been performed consulting for Novartis, Genentech Corporation, and JuneBrain LLC. He is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen. He previously received support from the Race to Erase MS foundation. He has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. He was also the site investigator of trials sponsored by MedDay Pharmaceuticals, Clene Pharmaceuticals, and is the site investigator of a trial sponsored by Novartis.